First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose

First-in-Human Trial of EphA2-Redirected CAR T-Cells in Patients With Recurrent Glioblastoma: A Preliminary Report of Three Cases at the Starting Dose

Glioblastoma is the most common primary brain malignancy with limited treatment options. EphA2 is a tumor-associated-antigen overexpressed in glioblastoma. Pre-clinical studies have demonstrated the promise of EphA2-redirected CAR T-cells against glioblastoma. We conduct the first-in-human trial of...

Full description

Bibliographic Details
Main Authors: Qingtang Lin, Teer Ba, Jinyuan Ho, Dandan Chen, Ye Cheng, Leiming Wang, Geng Xu, Lixin Xu, Yiqiang Zhou, Yukui Wei, Jianqiang Li, Feng Ling
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
chimeric antigen receptor (CAR T)
EphA2
glioma
clinical trial
immunotherapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.694941/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.694941/full

Similar Items